1. Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease Hughes, Tasha; Iodice, Gail M.; Basu, Sanjib; Bines, Steven; Kaufman, Howard 2013 Presentations (Communicative Events) Cancer--ImmunotherapyMelanoma--TreatmentRenal cell carcinomaInterleukin-2ImmunotherapyOncologyMedicineImmunology
2. The role of surgery following incomplete response to high-dose IL-2 (HD IL-2) Hughes, Tasha; Iodice, Gail M.; Basu, Sanjib; Bines, Steven; Kaufman, Howard 2013 Presentations (Communicative Events) Excision (Surgery)Metastasis--SurgeryMetastasisMetastasis--TreatmentCancer--SurgeryCancer--ImmunotherapyInterleukin-2OncologyMedicineSurgeryImmunology
3. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma Clark, Joseph I.; Singh, Jatinder; Ernstoff, Marc S.; Lao, Christopher D.; Flaherty, Lawrence E.; Logan, Theodore F.; Curti, Brendan; Agarwala, Sanjiv S.; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L.; Aung, Sandra; Lawson, David H. 2018 Articles Cancer--ImmunotherapyInterleukin-2Melanoma--TreatmentEnzyme inhibitors